CTRI/2021/02/031337招募中3 期
A Randomized, Multicenter, Active Controlled, Parallel-Group Study to Access Efficacy and Safety of Fixed Dose Combination of Netarsudil (0.02%) and Latanoprost (0.005%) Ophthalmic Solution in Comparison with Latanoprost (0.005%) Ophthalmic Solution in Patients with Open Angle Glaucoma or Ocular Hypertension
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects will be included in the study if they meet all of the following criteria:
- •1) Patients of either sex, aged 18 to 65 years (both inclusive) and ready to give written informed consent to participate in the study.
- •2) Diagnosis (new/old) of primary open angle glaucoma / ocular hypertension in at least one eye confirmed by Goldmann applanation tonometry.
- •3) IOP values
- •a. Newly diagnosed: IOP > 20 mmHg and < 36 mmHg at 9 AM in at least one eye at screening and day 1 (randomization day)
- •b. Old patients: Unmedicated (post-washout (refer note)) IOP > 20 mmHg and < 36 mmHg at 9 AM in at least one eye at day 1 (randomization day)
- •For purposes of determining eligibility of subjects to be randomized, IOP number should not be rounded off.
- •4) Best corrected visual acuity +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/40 (6/12) or better Snellen visual acuity in each eye)
- •5) Women of childbearing potential must have a negative urine pregnancy test prior to study entry and agree to use highly effective methods of contraception to prevent pregnancy from study entry till the last dose of the study medication (such contraception may include hormonal birth control e.g., combined estrogen and progestogen containing [oral, intravaginal, or transdermal] or progesterone only [oral, injectable, or implantable] hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone releasing system OR bilateral tubal occlusion, vasectomized partner, or sexual abstinence)
- •[Note: Woman with childbearing potential are defined as: those who are not (1) surgically sterile (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation) or (2) post-menopausal]
- •6) A female patient of non-childbearing potential such as (1) surgically sterile (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation) or (2) post-menopausal.
- •[Note: Post-menopausal woman will be defined as: Woman not using hormonal replacement therapy and have had at least 12 continuous months of natural (spontaneous) amenorrhea and be greater than 45 years of age]
- •Note: Ocular Hypotensive Medication Washout Period
- •Prostaglandin analogues- 4 weeks
- •Ã?²-adrenoceptor antagonists- 4 weeks
- •Adrenergic agonists (including Ã?±-agonists such as brimonidine and apraclonidine)- 2 weeks
- •Muscarinic agonists (eg, pilocarpine), carbonic anhydrase inhibitors (topical or oral)- 5 days
排除标准
- •Subject will be deemed ineligible to participate in the study if he/she fulfils any of the following criteria:
- •Ophthalmic:
- •1) Clinically significant ocular disease (eg, corneal edema, uveitis, or severe keratoconjunctivitis sicca) which might interfere with interpretation of the study efficacy endpoints or with safety assessments, including subjects with glaucomatous damage based on field effect so severe that washout of ocular hypotensive medications for 1 month is not judged safe as it would put the subject at risk for further vision loss. (The Investigator will be encouraged to conduct interim visits (unscheduled visits) during the washout period for IOP measurements for individuals to whom a washout period may be a risk for further glaucomatous progression)
- •2) Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles (ie, Shaffer Grade 2 or less; extreme narrow angle with complete or partial closure). Note: Previous laser peripheral iridotomy is NOT acceptable
- •3) Use of more than two ocular hypotensive medications within 28 days of screening. Note: fixed dose combination medications, for the purpose of this exclusion criterion, count as one medication
- •4) Known hypersensitivity to any component of the investigational formulations or to Latanoprost
- •5) Previous glaucoma intraocular surgery, including SLT or ALT in either eye
- •6) Refractive surgery in either eye (eg, radial keratotomy, PRK, LASIK, corneal cross-linking)
- •7) Ocular trauma within six months prior to screening, or ocular surgery or non-refractive laser treatment within three months prior to screening
- •8) Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of clinically significant blepharitis, conjunctivitis, keratitis, or a history of herpes simplex or zoster keratitis in either eye at screening
- •9) Use of ocular medication in either eye of any kind within 30 days of screening and throughout the study, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after, screening), c) lubricating drops for dry eye (which may be used throughout the study), or d) non-steroid allergy drops (note: must not contain a vasoconstrictor) as prescribed by the Investigator.
- •10) Mean central corneal thickness greater than 580 Ã?¼m at screening
- •11) Any abnormality preventing reliable applanation tonometry of either eye (eg, keratoconus)
- •12) Subjects who are blind or subjects who have a single eye
- •13) History of clinically relevant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment.
- •14) Subjects using contact lenses.
- •15) Subjects having local administration of corticosteroids injections in the eye
- •16) Participation in any investigational study within 30 days prior to screening
- •17) Systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study, including any corticosteroid-containing drug regardless of route of administration
- •18) Subjects with history of CVS, Hepatic, Psychiatric, Cancer or Renal diseases which could be considered significant for the subject to be enrolled in the study
研究者
相似试验
终止
不适用
Phase IV Clinical Trial to Evaluate in Children with Symptom Contral due to Persistent Allergic RhinitisDiseases of th respiratory systemKCT0000972Dong Hwa Pharm100
已完成
3 期
A Phase III study understand the,Efficacy, Safety and Tolerability Study of Sugammadex Injection 100mg/ml as compared with Neostigmine Methylsulfate Injection 0.5mg/ml in subjects scheduled for surgical procedure with Shallow Neuromuscular BlockadeCTRI/2021/08/035471BDR Pharmaceuticals Internationals Pvt Ltd
尚未招募
不适用
A Multi-center, Randomized, Active-controlled, Parallel Design, Low-Intervention Clinical Trial; Pitavastatin Comparing with Atorvastatin in Patients with Pre-Diabetes Mellitus and Hypercholesterolemia for evaluate the New Onset Diabetes Mellitus (PIANO-DM study)Endocrine, nutritional and metabolic diseaseKCT0005394The Catholic University of Korea, Bucheon St. Mary's Hospital706
已完成
2 期
Clinical Study of Dabur Hepano tablet in comparison with a marketed Hepatoprotective formulation in Liver Disorder PatientsCTRI/2014/02/004410Dabur India Limited180
进行中（未招募）
1 期
Clinical study investigating efficacy and safety of BT524 in intra-operative use in patients undergoing major spine surgeryElective spine surgery with expected major blood lossMedDRA version: 20.0Level: PTClassification code 10051125Term: HypofibrinogenaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2017-001163-20-BEBiotest AG200